Liver Replacement Therapy

被引:28
作者
Tritto, Giovanni [1 ]
Davies, Nathan A. [1 ]
Jalan, Rajiv [1 ]
机构
[1] UCL, Sch Med, Royal Free Hosp, Liver Failure Grp,Inst Hepatol, London W1N 8AA, England
关键词
liver failure; extracorporeal liver support; albumin dialysis; bioartificial liver; PORCINE ENDOGENOUS RETROVIRUS; ADSORBENTS RECIRCULATING SYSTEM; FULMINANT HEPATIC-FAILURE; PASS ALBUMIN DIALYSIS; BIOARTIFICIAL LIVER; PHASE-I; CONTROLLED-TRIAL; ASSIST DEVICE; BLOOD-FLOW; SUPPORT;
D O I
10.1055/s-0032-1301736
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
The realization of a support device able to effectively replace liver function in patients with hepatic failure has thus far been an elusive goal. The complexity of liver metabolic, synthetic, detoxifying, and excretory functions make artificial hepatic support extremely challenging. Currently, no specific treatment is available to reverse acute or acute-on-chronic liver failure, and morbidity and mortality of these syndromes are still high. Present management strategies are supportive, while waiting for spontaneous liver regeneration or liver transplant. Because of the scarcity of donor organs, liver support strategies are needed for patients with inadequate liver function until an appropriate organ becomes available for transplantation or until their liver recovers from injury. Currently available liver support systems comprise nonbiological systems (e.g., hemodiafiltration, albumin dialysis, and plasma exchange) and bioartificial systems utilizing viable liver cells. The role for these novel systems and their impact on survival or other clinically important outcomes are controversial. Development and use of bioartificial systems are limited by the inherent cost.
引用
收藏
页码:70 / 79
页数:10
相关论文
共 58 条
  • [1] Advances in bioartificial liver devices
    Allen, JW
    Hassanein, T
    Bhatia, SN
    [J]. HEPATOLOGY, 2001, 34 (03) : 447 - 455
  • [2] Bañares R, 2010, J HEPATOL, V52, pS459
  • [3] Which are the right cells to be used in a bioartificial liver?
    Chamuleau, RAFM
    Deurholt, T
    Hoekstra, R
    [J]. METABOLIC BRAIN DISEASE, 2005, 20 (04) : 327 - 335
  • [4] Chen Y, 2007, CELL TRANSPLANT, V16, P97
  • [5] Hepatic blood flow and splanchnic oxygen consumption in patients with liver failure.: Effect of high-volume plasmapheresis
    Clemmesen, JO
    Gerbes, AL
    Gülberg, V
    Hansen, BA
    Larsen, FS
    Skak, C
    Tygstrup, N
    Ott, P
    [J]. HEPATOLOGY, 1999, 29 (02) : 347 - 355
  • [6] Prospective, randomized, multicenter, controlled trial of a bioartificial liver in treating acute liver failure
    Demetriou, AA
    Brown, RS
    Busuttil, RW
    Fair, J
    McGuire, BM
    Rosenthal, P
    Esch, JSA
    Lerut, J
    Nyberg, SL
    Salizzoni, M
    Fagan, EA
    de Hemptinne, B
    Broelsch, CE
    Muraca, M
    Salmeron, JM
    Rabkin, JM
    Metselaar, HJ
    Pratt, D
    De La Mata, M
    McChesney, LP
    Everson, GT
    Lavin, PT
    Stevens, AC
    Pitkin, Z
    Solomon, BA
    [J]. ANNALS OF SURGERY, 2004, 239 (05) : 660 - 667
  • [7] No evidence of in vitro and in vivo porcine endogenous retrovirus infection after plasmapheresis through the AMC-bioartificial liver
    Di Nicuolo, G
    van de Kerkhove, MP
    Hoekstra, R
    Beld, MGHM
    Amoroso, P
    Battisti, S
    Starace, M
    di Florio, E
    Scuderi, V
    Scala, S
    Bracco, A
    Mancini, A
    Chamuleau, RAFM
    Calise, F
    [J]. XENOTRANSPLANTATION, 2005, 12 (04) : 286 - 292
  • [8] Duan ZP, 2007, HEPATOLOGY, V46, p274A
  • [9] Ellis AJ, 1996, HEPATOLOGY, V24, P1446, DOI 10.1002/hep.510240625
  • [10] Prometheus versus molecular adsorbents recirculating system: Comparison of efficiency in two different liver detoxification devices
    Evenepoel, P
    Laleman, T
    Wilmer, A
    Claes, K
    Kuypers, D
    Barnmens, B
    Nevens, F
    Vanrenterghem, Y
    [J]. ARTIFICIAL ORGANS, 2006, 30 (04) : 276 - 284